A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

Drug repurposing is the only method capable of delivering treatments on the shortened time-scale required for patients afflicted with lung disease arising from SARS-CoV-2 infection. Mucin-1 (MUC1), a membrane-bound molecule expressed on the apical surfaces of most mucosal epithelial cells, is a bioc...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:bioRxiv
Päätekijät: Alimova, Maria, Sidhom, Eriene-Heidi, Satyam, Abhigyan, Dvela-Levitt, Moran, Melanson, Michelle, Chamberlain, Brian T., Alper, Seth L., Santos, Jean, Gutierrez, Juan, Subramanian, Ayshwarya, Grinkevich, Elizabeth, Bricio, Estefania Reyes, Kim, Choah, Clark, Abbe, Watts, Andrew, Thompson, Rebecca, Marshall, Jamie, Pablo, Juan Lorenzo, Coraor, Juliana, Roignot, Julie, Vernon, Katherine A., Keller, Keith, Campbell, Alissa, Emani, Maheswarareddy, Racette, Matthew, Bazua-Valenti, Silvana, Padovano, Valeria, Weins, Astrid, McAdoo, Stephen P., Tam, Frederick W.K., Ronco, Lucienne, Wagner, Florence, Tsokos, George C., Shaw, Jillian L., Greka, Anna
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Cold Spring Harbor Laboratory 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7337390/
https://ncbi.nlm.nih.gov/pubmed/32637960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.06.30.180380
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia